Status:
COMPLETED
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)
Lead Sponsor:
Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo Company
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Hong Kong proposed this non-interventional study (NIS) to gain ins...
Detailed Description
Edoxaban was approved by the Pharmacy and Poisons Board in Hong Kong (date: 31 May 2016) for the: Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVA...
Eligibility Criteria
Inclusion
- Is a NVAF-patient whose physician has made the clinical decision to prescribe edoxaban therapy according to Package Information
- Has provided written informed consent to participate in the study
Exclusion
- Is participating in an interventional study
Key Trial Info
Start Date :
August 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 3 2022
Estimated Enrollment :
234 Patients enrolled
Trial Details
Trial ID
NCT03247582
Start Date
August 2 2017
End Date
May 3 2022
Last Update
August 18 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital (1082)
Hong Kong, Hong Kong
2
Prince of Wales Hospital (1083)
Hong Kong, Hong Kong
3
Queen Mary Hospital, Department of Cardiology (1801)
Hong Kong, Hong Kong
4
Queen Mary Hospital, Department of Neurology (1805)
Hong Kong, Hong Kong